Literature DB >> 27376675

RNA-based therapies for genodermatoses.

Olivier Bornert1, Patricia Peking2, Jeroen Bremer3, Ulrich Koller2, Peter C van den Akker3,4, Annemieke Aartsma-Rus5, Anna M G Pasmooij3, Eva M Murauer2, Alexander Nyström1.   

Abstract

Genetic disorders affecting the skin, genodermatoses, constitute a large and heterogeneous group of diseases, for which treatment is generally limited to management of symptoms. RNA-based therapies are emerging as a powerful tool to treat genodermatoses. In this review, we discuss in detail RNA splicing modulation by antisense oligonucleotides and RNA trans-splicing, transcript replacement and genome editing by in vitro-transcribed mRNAs, and gene knockdown by small interfering RNA and antisense oligonucleotides. We present the current state of these therapeutic approaches and critically discuss their opportunities, limitations and the challenges that remain to be solved. The aim of this review was to set the stage for the development of new and better therapies to improve the lives of patients and families affected by a genodermatosis.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  RNA trans-splicing; antisense oligonucleotides; in vitro-transcribed mRNA; siRNA; skin

Mesh:

Substances:

Year:  2017        PMID: 27376675      PMCID: PMC5593095          DOI: 10.1111/exd.13141

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  87 in total

1.  RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin.

Authors:  Jurgen Harder; Jens-Michael Schroder
Journal:  J Biol Chem       Date:  2002-09-18       Impact factor: 5.157

2.  158th ENMC international workshop on congenital muscular dystrophy (Xth international CMD workshop) 8th-10th February 2008 Naarden, The Netherlands.

Authors:  F Muntoni; P Guicheney; T Voit
Journal:  Neuromuscul Disord       Date:  2008-12-18       Impact factor: 4.296

3.  A reporter-based screen to identify potent 3' trans-splicing molecules for endogenous RNA repair.

Authors:  Eva M Murauer; Ulrich Koller; Stefan Hainzl; Verena Wally; Johann W Bauer
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

4.  Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells.

Authors:  Xiaoming Liu; Meihui Luo; Liang N Zhang; Ziying Yan; Roman Zak; Wei Ding; S Gary Mansfield; Lloyd G Mitchell; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

5.  TALEN-based gene correction for epidermolysis bullosa.

Authors:  Mark J Osborn; Colby G Starker; Amber N McElroy; Beau R Webber; Megan J Riddle; Lily Xia; Anthony P DeFeo; Richard Gabriel; Manfred Schmidt; Christof von Kalle; Daniel F Carlson; Morgan L Maeder; J Keith Joung; John E Wagner; Daniel F Voytas; Bruce R Blazar; Jakub Tolar
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

6.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

Authors:  Michael S D Kormann; Günther Hasenpusch; Manish K Aneja; Gabriela Nica; Andreas W Flemmer; Susanne Herber-Jonat; Marceline Huppmann; Lauren E Mays; Marta Illenyi; Andrea Schams; Matthias Griese; Iris Bittmann; Rupert Handgretinger; Dominik Hartl; Joseph Rosenecker; Carsten Rudolph
Journal:  Nat Biotechnol       Date:  2011-01-09       Impact factor: 54.908

7.  Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Marta Garcia; Renske Brander; Cristina Has; Rowdy Meijer; Maria Jose Escámez; Jürgen Kohlhase; Peter C van den Akker; Hans Scheffer; Marcel F Jonkman; Marcela Del Rio; Leena Bruckner-Tuderman; Anna M G Pasmooij
Journal:  J Invest Dermatol       Date:  2014-02-27       Impact factor: 8.551

8.  A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.

Authors:  Patricia Peking; Ulrich Koller; Stefan Hainzl; Sophie Kitzmueller; Thomas Kocher; Elisabeth Mayr; Alexander Nyström; Thomas Lener; Julia Reichelt; Johann W Bauer; Eva M Murauer
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-01       Impact factor: 10.183

9.  Keratin 9 is required for the structural integrity and terminal differentiation of the palmoplantar epidermis.

Authors:  Dun Jack Fu; Calum Thomson; Declan P Lunny; Patricia J Dopping-Hepenstal; John A McGrath; Frances J D Smith; W H Irwin McLean; Deena M Leslie Pedrioli
Journal:  J Invest Dermatol       Date:  2013-08-20       Impact factor: 8.551

10.  Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.

Authors:  Cristina Chamorro; Angeles Mencía; David Almarza; Blanca Duarte; Hildegard Büning; Jessica Sallach; Ingrid Hausser; Marcela Del Río; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther Nucleic Acids       Date:  2016-04-05       Impact factor: 10.183

View more
  11 in total

1.  RNA Trans-Splicing Modulation via Antisense Molecule Interference.

Authors:  Bernadette Liemberger; Josefina Piñón Hofbauer; Verena Wally; Claudia Arzt; Stefan Hainzl; Thomas Kocher; Eva M Murauer; Johann W Bauer; Julia Reichelt; Ulrich Koller
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

Review 2.  Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.

Authors:  Cristina Has; Andrew South; Jouni Uitto
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

Review 3.  Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease.

Authors:  Catherine Baker; Matthew S Hayden
Journal:  F1000Res       Date:  2020-04-23

4.  An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex.

Authors:  P Peking; J S Breitenbach; M Ablinger; W H Muss; F J Poetschke; T Kocher; U Koller; S Hainzl; S Kitzmueller; J W Bauer; J Reichelt; T Lettner; V Wally
Journal:  Br J Dermatol       Date:  2018-10-07       Impact factor: 9.302

Review 5.  Epidermolysis bullosa: Advances in research and treatment.

Authors:  Christine Prodinger; Julia Reichelt; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2019-08-08       Impact factor: 3.960

Review 6.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

7.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123

Review 8.  Context-Dependent Strategies for Enhanced Genome Editing of Genodermatoses.

Authors:  Oliver Patrick March; Thomas Kocher; Ulrich Koller
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

9.  Therapies for epidermolysis bullosa: delivery is key.

Authors:  J Bremer; P C van den Akker
Journal:  Br J Dermatol       Date:  2019-01       Impact factor: 9.302

10.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.